Severe asthma exacerbations associated with short-acting beta 2 agonist use

Increasing exposure to short-acting beta 2 agonist rescue or reliever medication appeared associated with greater risk for severe asthma exacerbations regardless of inhaled corticosteroid use, according to study results.
Published in The Journal of Allergy and Clinical Immunology: In Practice, the study results suggest that rescue/reliever management using short-acting beta 2 agonist (SABA) monotherapy should be avoided, according to the researchers.
Jennifer K. Quint, MD, PhD, FRCP, professor of respiratory epidemiology at Imperial College London National Heart and Lung Institute, and

Increasing exposure to short-acting beta 2 agonist rescue or reliever medication appeared associated with greater risk for severe asthma exacerbations regardless of inhaled corticosteroid use, according to study results.
Published in The Journal of Allergy and Clinical Immunology: In Practice, the study results suggest that rescue/reliever management using short-acting beta 2 agonist (SABA) monotherapy should be avoided, according to the researchers.
Jennifer K. Quint, MD, PhD, FRCP, professor of respiratory epidemiology at Imperial College London National Heart and Lung Institute, and